Kronos Bio

Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. Its pipeline includes hematologic malignancies, prostate cancer, MYC-driven cancers, and small cell/neuroendocrine cancers. The company was founded by Angela Koehler and Joshua A. Kazam in 2017 and is headquartered in San Mateo, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.

Roche Holding AG

Shares of Kronos Bio Inc. KRON, +2.38% jumped 25% in premarket trading on Monday after the company announced a development deal with Roche Holding's ROG, -0.46% Genentech. Kronos has a drug discovery platform that will be used to support Genentech's research in small-molecule drugs for cancer.

Kronos Bio's stock rallies after announcing drug-discovery deal with Roche

Kronos Bio will receive a $20 million upfront payment and could receive up to an additional $554 million in milestone payments

Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology

Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 31% in 4 Weeks

Lanraplenib is being evaluated in ongoing Phase 1b/2 trial in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated AML

Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting

Kronos Bio to move into Phase 2 stage of study, evaluating compound in patients with MYC-amplified and other transcriptionally addicted tumors

Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial

Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 23.8% in 4 Weeks

Earlier today, the company announced prioritization of clinical portfolio to focus on next-generation SYK inhibitor, lanraplenib and CDK9 inhibitor, KB-0742

Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results

Company to discontinue Phase 3 entospletinib trial for strategic reasons

Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

ANGI Homeservices

Farfetch

IHS Holding Ltd

Rent the Runway

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Goldman Sachs Has 5 Stocks to Buy Under $10 With 100% to 800% Upside Potential

Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742 Phase 1/2 Clinical Trial in Q4 2022 Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742 Phase 1/2 Clinical Trial in Q4 2022

Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022

SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the H.C. Wainwright 24th Annual Global Investment Conference. An on-demand webcast of the presentation will be available on Monday, September 12, 2022, at 7 a.m. ET.

Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference

SAN MATEO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in a Phase 1b/2 clinical trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).

Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia

Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML Entospletinib is currently being studied in the Phase 3 AGILITY registrational study, with data anticipated in second half of 2023 SAN MATEO, Calif. and SAN DIEGO , Aug. 16, 2022 /PRNewswire/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of diagnostic kits and services for oncology, today announced their agreement to develop a companion diagnostic (CDx) for use with Kronos Bio's investigational therapy, entospletinib.

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

The consensus price target hints at a 311.9% upside potential for Kronos Bio, Inc. (KRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Kronos Bio, Inc. (KRON) Climb 312% to Reach the Level Wall Street Analysts Expect?

Company continuing to enroll patients in both Phase 3 registrational AGILITY trial of entospletinib and Phase 1/2 KB-0742 trial; both programs remain on track

Kronos Bio Reports Recent Business Progress and Second-Quarter 2022 Financial Results

Cricut

GreenPower Motor Co.

Lyft

Netflix

PayPal

Veritone

If you want to maximize your return potential and can handle some heat, here are compelling Nasdaq stocks to buy on the dip. The post 7 Nasdaq Stocks to Buy on the Dip appeared first on InvestorPlace.

7 Nasdaq Stocks to Buy on the Dip

Kronos Bio, Inc. (KRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Kronos Bio, Inc. (KRON) Upgraded to Buy: Here's What You Should Know

Posters include preclinical data on SYK inhibition in combination with targeted agents suggesting evidence of preclinical anti-tumor activity in acute myeloid leukemia Posters include preclinical data on SYK inhibition in combination with targeted agents suggesting evidence of preclinical anti-tumor activity in acute myeloid leukemia

Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress

Zevia PBC

Biotech Dominates Goldman Sachs 5 Buy-Rated Stocks Under $10 With 400% to 800% Upside Potential

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the H.C. Wainwright Global Investment Conference. An on-demand webcast of the presentation will be available on Tuesday, May 24, 2022, at 7 a.m. ET.

Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference

Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical anti-tumor activity in acute myeloid leukemia (AML)

Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress

Preclinical data on CDK9 inhibitor KB-0742 presented at AACR add to evidence of potential activity in MYC-amplified and transcriptionally addicted tumors; company plans to announce RP2D and  additional Phase 1 data in Q4 2022

Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results

Array Technologies

Genius Sports

Lulu's Fashion Lounge Holdings

Goldman Sachs Has 5 Stocks Rated Buy Under $10 With 75% to 500% Upside Potential

Preclinical data featured in three posters show potential of KB-0742 in triple-negative breast, lung and ovarian cancers, as well as lymphoma and rare, soft-tissue cancers, including  sarcoma and chordoma

Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR

AvePoint

Compass

Planet Labs

Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With Up to 600% Upside Potential

News for Kronos Bio Stock (KRON)